锡罗斯对耐火/复发性异常多中心卡斯特曼病有效:一个单中心的回顾性研究
Yan-Ting Liu1, Yu-Han Gao1, Hao Zhao1
1Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Annals of hematology
|May 1, 2024
概括
赛洛斯为耐火/复发性异常多中心卡斯特曼病 (R/R iMCD) 提供了一个有前途的治疗方法. 这项研究发现,西洛斯在R/R iMCD患者中有效且耐受良好,大多数患者实现了持续缓解.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 耐药/复发性异常多中心卡斯特曼病 (R/R iMCD) 具有有限的治疗途径.
- 在iMCD患者中观察到mTOR通路激活的增加,这表明有针对性的治疗潜力.
研究的目的:
- 评估西洛斯在R/R iMCD患者中的疗效和安全性.
- 评估治疗反应,缓解持续时间和基于西罗的治疗方案的耐受性.
主要方法:
- 对26名R/R iMCD患者进行了回顾性分析,这些患者接受了含西洛斯的治疗方案.
- 收集关于患者人口统计,先前治疗,反应率,缓解时间和不良事件的数据.
主要成果:
- 26名患者中有18名 (69.2%) 获得了症状和生化反应.
- 部分缓解的中位时间为1.9个月,下一次治疗的中位时间为46.2个月.
- 雪洛利马斯耐受性很好,但有轻微的不良反应;在随访期间没有报告死亡.
结论:
- 赛洛斯在治疗R/R iMCD方面表现出显著的疗效.
- 该药物耐受性良好,为这种患者群体提供了可行的和有效的治疗选择.
相关概念视频
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...